What is lecanemab and how does it slow down Alzheimer's disease?
A new Health Canada-approved drug called lecanemab has been shown to slow early-stage Alzheimer's disease. Neurologist Dr. Sharon Cohen, who participated in phase three trials for the drug, explains why lecanemab is such a big deal.For transcripts of The Dose, please visit: lnk.to/dose-transcripts. Transcripts of each episode will be made available by the next workday. For more episodes of this podcast, click this link.
The Dose · CBC
Audio is streamed directly from the publisher (mgln.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A new Health Canada-approved drug called lecanemab has been shown to slow early-stage Alzheimer's disease. Neurologist Dr. Sharon Cohen, who participated in phase three trials for the drug, explains why lecanemab is such a big deal.
For transcripts of The Dose, please visit: lnk.to/dose-transcripts. Transcripts of each episode will be made available by the next workday. For more episodes of this podcast, click this link.